OM
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition | npj precision oncology |  | 2024 | 10 | 2 | ||
| Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy | Cell | | 2024 | 662 | 146 | ||
| Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma | Science immunology |  | 2024 | 98 | 0 | ||
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | | 2023 | 32 | 15 | ||
| Testing a model of care for patients on immune checkpoint inhibitors based on electronic patient-reported outcomes : protocol for a randomized phase II controlled trial | JMIR research protocols | | 2023 | 52 | 27 | ||
| Neoadjuvant immunotherapy : a promising new standard of care | International journal of molecular sciences | | 2023 | 74 | 42 | ||
| Novel targets for immune-checkpoint inhibition in cancer | Cancer treatment reviews | | 2023 | 48 | 28 | ||
| Dendritic cells direct circadian anti-tumour immune responses | Nature | | 2023 | 659 | 163 | ||
| Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient | Cancer biology & therapy | | 2023 | 45 | 8 | ||
| Towards a national strategy for digital pathology in Switzerland | Virchows Archiv | | 2022 | 188 | 50 | ||
| Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab | Gynecologic Oncology Reports | | 2021 | 222 | 73 | ||
| The Peroxisomal Enzyme L-PBE Is Required to Prevent the Dietary Toxicity of Medium-Chain Fatty Acids | Cell Reports | | 2013 | 236 | 89 |
